RBTT-05. A SINGLE-ARM, OPEN-LABEL, PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF ABEMACICLIB IN PATIENTS WITH RECURRENT OLIGODENDROGLIOMA: TRIALS IN PROGRESS

BACKGROUND: Oligodendroglioma is a rare primary brain tumor characterized by mutation in the IDH1/IDH2 genes and codeletion of chromosomes 1p and 19q. Although median overall survival extends beyond 10 years for patients with oligodendroglioma who receive adjuvant radiation and alkylating chemothera...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Neuro Oncol
Glavni autori: Bagley, Stephen, Nasrallah, MacLean, O’Rourke, Donald, Hussain, Jasmin, Maloney-Wilensky, Eileen, Prior, Timothy, Brem, Steven, Desai, Arati
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2019
Teme:
Randomized Brain Tumor Trials in Development
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6847756/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.917
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items